Buy Or Sell Opportunity • Jun 10
Now 21% undervalued Over the last 90 days, the stock has risen 7.3% to ₹978. The fair value is estimated to be ₹1,241, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 61% in the next 2 years. Reported Earnings • May 19
Full year 2026 earnings: EPS misses analyst expectations Full year 2026 results: EPS: ₹60.34 (up from ₹44.05 in FY 2025). Revenue: ₹50.1b (up 9.7% from FY 2025). Net income: ₹5.56b (up 37% from FY 2025). Profit margin: 11% (up from 8.9% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.1%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth. Ankündigung • May 11
Strides Pharma Science Limited to Report Q4, 2026 Results on May 18, 2026 Strides Pharma Science Limited announced that they will report Q4, 2026 results on May 18, 2026 Price Target Changed • Mar 20
Price target increased by 15% to ₹1,247 Up from ₹1,083, the current price target is an average from 2 analysts. New target price is 38% above last closing price of ₹905. Stock is up 29% over the past year. The company is forecast to post earnings per share of ₹62.30 for next year compared to ₹44.05 last year. Reported Earnings • Jan 31
Third quarter 2026 earnings released: EPS: ₹21.93 (vs ₹9.56 in 3Q 2025) Third quarter 2026 results: EPS: ₹21.93 (up from ₹9.56 in 3Q 2025). Revenue: ₹11.9b (up 3.6% from 3Q 2025). Net income: ₹2.02b (up 130% from 3Q 2025). Profit margin: 17% (up from 7.6% in 3Q 2025). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Ankündigung • Jan 23
Strides Pharma Science Limited to Report Q3, 2026 Results on Jan 30, 2026 Strides Pharma Science Limited announced that they will report Q3, 2026 results on Jan 30, 2026 Buy Or Sell Opportunity • Jan 09
Now 21% undervalued Over the last 90 days, the stock has risen 11% to ₹943. The fair value is estimated to be ₹1,198, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 93% in the next 2 years. Buy Or Sell Opportunity • Dec 24
Now 22% undervalued Over the last 90 days, the stock has risen 12% to ₹938. The fair value is estimated to be ₹1,197, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 93% in the next 2 years. Buy Or Sell Opportunity • Nov 07
Now 21% undervalued Over the last 90 days, the stock has risen 18% to ₹947. The fair value is estimated to be ₹1,195, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 92% in the next 2 years. Reported Earnings • Nov 01
Second quarter 2026 earnings released: EPS: ₹13.84 (vs ₹10.14 in 2Q 2025) Second quarter 2026 results: EPS: ₹13.84 (up from ₹10.14 in 2Q 2025). Revenue: ₹12.5b (up 3.9% from 2Q 2025). Net income: ₹1.28b (up 37% from 2Q 2025). Profit margin: 10% (up from 7.8% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth. Ankündigung • Oct 24
Strides Pharma Science Limited to Report Q2, 2026 Results on Oct 31, 2025 Strides Pharma Science Limited announced that they will report Q2, 2026 results on Oct 31, 2025 Ankündigung • Jul 23
Strides Pharma Science Limited to Report Q1, 2026 Results on Jul 29, 2025 Strides Pharma Science Limited announced that they will report Q1, 2026 results on Jul 29, 2025 Upcoming Dividend • Jul 15
Upcoming dividend of ₹4.00 per share Eligible shareholders must have bought the stock before 22 July 2025. Payment date: 06 September 2025. Payout ratio is a comfortable 9.1% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.8%). Ankündigung • Jul 10
Strides Pharma Science Limited announces Annual dividend, payable on September 06, 2025 Strides Pharma Science Limited announced Annual dividend of INR 4.0000 per share payable on September 06, 2025, ex-date on July 22, 2025 and record date on July 22, 2025. Ankündigung • Jul 09
Strides Pharma Science Limited, Annual General Meeting, Aug 07, 2025 Strides Pharma Science Limited, Annual General Meeting, Aug 07, 2025, at 11:30 Indian Standard Time. New Risk • Jun 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.5x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.1% average weekly change). Price Target Changed • May 23
Price target increased by 7.3% to ₹1,482 Up from ₹1,381, the current price target is an average from 2 analysts. New target price is 102% above last closing price of ₹733. The company is forecast to post earnings per share of ₹51.90 for next year compared to ₹44.05 last year. Ankündigung • May 16
Strides Pharma Science Limited to Report Q4, 2025 Results on May 22, 2025 Strides Pharma Science Limited announced that they will report Q4, 2025 results on May 22, 2025 Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹584, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 286% over the past three years. New Risk • Apr 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (93% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (8.5% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹701, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 362% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹1,394 per share. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹620, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 319% over the past three years. New Risk • Jan 31
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks High level of debt (89% net debt to equity). Paying a dividend despite being loss-making. Large one-off items impacting financial results. Ankündigung • Jan 30
Strides Pharma Science Limited Announces Re-Designation of Arun Kumar from Executive Chairperson to Non Executive Chairperson Effective April 5, 2025 Strides Pharma Science Limited announced the re-designation of Mr. Arun Kumar from Executive Chairperson to Non Executive Chairperson effective April 5, 2025. Mr. Arun Kumar (DIN: 00084845) is currently the Executive Chairperson of the Company. In May 22, 2024, as part of the strengthening the diversification of Board and succession planning, Arun transitioned to a Executive Chairperson position from Chairperson and Managing Director. Upon successful transition of executive responsibilities to Mr. Badree Komandur, who was appointed as Managing Director and Group CEO effective June 1, 2024. Ankündigung • Jan 24
Strides Pharma Science Limited to Report Q3, 2025 Results on Jan 30, 2025 Strides Pharma Science Limited announced that they will report Q3, 2025 results on Jan 30, 2025 Price Target Changed • Dec 24
Price target decreased by 13% to ₹1,486 Down from ₹1,701, the current price target is an average from 4 analysts. New target price is 116% above last closing price of ₹688. The company is forecast to post earnings per share of ₹40.30 next year compared to a net loss per share of ₹13.72 last year. Ankündigung • Dec 12
Strides Pharma Science Limited completed the Spin-Off of OneSource Specialty Pharma Limited. Strides Pharma Science Limited (NSEI:STAR) announced the spin-off of Stelis Biopharma Private Limited on February 4, 2021. As per the transaction, shareholders of Strides Pharma Science Limited will receive 1 equity share of Stelis Biopharma Private Limited for every 2 equity shares held. The Board of Strides Pharma will form a Committee of Directors to explore various options of value discovery including listing of the business on a standalone basis. The Committee will recommend the proposals to the Audit Committee, Committee of Independent Directors and Board including the Scheme, swap ratio and way forward. Strides is also considering retaining a minority treasury investment in Stelis. The spin-off is subject to approval from Strides Pharma shareholders, meeting customary closing conditions and is expected to achieve closure in over 12 months. As of May 22, 2024, Transaction has received approval from Stock exchanges and SEBI. Filing with NCLT to be completed in Q1FY25. As of July 30, 2024, NCLT Order directs all participating companies to inter alia, convene meeting of its equity shareholders and secured creditors. As of November 27, 2024, NCLT has approved the scheme on November 14, 2024. Jefferies India Private Limited acted as a financial advisor to Strides Pharma.
Strides Pharma Science Limited (NSEI:STAR) completed the spin-off of OneSource Specialty Pharma Limited on December 10, 2024. OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited) have completed allotment of Equity Shares on December 10, 2024, to eligible Shareholders of the Strides Pharma as of the Record of December 6, 2024. OneSource will proceed with the listing of its shares on the stock exchange and expecting to receive Listing Approval from the Stock Exchanges during Q4 FY 25. New Risk • Dec 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Paying a dividend despite being loss-making. Buy Or Sell Opportunity • Dec 06
Now 59% undervalued after recent price drop Over the last 90 days, the stock has fallen 48% to ₹713. The fair value is estimated to be ₹1,724, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 24% in 2 years. Earnings are forecast to grow by 270% in the next 2 years. Ankündigung • Nov 21
Strides Pharma Science Limited Announces Appointment of Dr. C Muthulingam as Executive Vice President - Research & Development Strides Pharma Science Limited informed that Dr. C Muthulingam has been appointed as Executive Vice President - Research & Development of the Company effective November 21, 2024. Dr. Muthu is a qualified pharmacy professional having around 22 years of industrial research experience. He holds a Doctorate Degree from Jaipur National University, specialized in Pharmaceutical Sciences. He also holds a Post Graduate Diploma in International Business Management from Symbiosis Centre for Distance Learning, Pune. Dr. Muthu was last associated with Mankind Pharma. He has also worked with other pharma companies viz., Aurobindo Pharma, Alembic Ltd, Piramal Healthcare, Ranbaxy, Dr. Reddy's, amongst others. Reported Earnings • Oct 25
Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹10.14 (up from ₹14.54 loss in 2Q 2024). Revenue: ₹12.0b (up 20% from 2Q 2024). Net income: ₹932.3m (up ₹2.25b from 2Q 2024). Profit margin: 7.8% (up from net loss in 2Q 2024). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth. Ankündigung • Oct 18
Strides Pharma Science Limited to Report Q2, 2025 Results on Oct 24, 2024 Strides Pharma Science Limited announced that they will report Q2, 2025 results on Oct 24, 2024 Upcoming Dividend • Sep 02
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 09 September 2024. Payment date: 25 October 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%). Ankündigung • Jul 30
Strides Pharma Science Limited Announces Completion of Tenure of S Sridhar as Independent Director Strides Pharma Science Limited informed that Mr. S Sridhar has completed his tenure as Independent Director of the Company with effect from closing business hours of July 30, 2024. Mr. Sridhar is associated with Strides since July 2012. He was part of the Audit Committee since his appointment and as Chairperson of the Audit Committee since May 2014. Sridhar has also been a member of other Board Committees at Strides. His rich experience in the financial services sector and expertise in the fields of banking and finance has immensely benefited the Company. Mr. S Sridhar has completed his
second and final term as Independent Director of the Company with effect from closing business hours of July 29, 2024. Reported Earnings • Jul 30
First quarter 2025 earnings released: EPS: ₹7.64 (vs ₹0.79 loss in 1Q 2024) First quarter 2025 results: EPS: ₹7.64 (up from ₹0.79 loss in 1Q 2024). Revenue: ₹10.9b (up 17% from 1Q 2024). Net income: ₹702.0m (up ₹773.2m from 1Q 2024). Profit margin: 6.5% (up from net loss in 1Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Ankündigung • Jul 22
Strides Pharma Science Limited to Report Q1, 2025 Results on Jul 29, 2024 Strides Pharma Science Limited announced that they will report Q1, 2025 results on Jul 29, 2024 Board Change • Jun 24
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. Executive Director of Business Development & Director Aditya Kumar was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • May 24
Price target increased by 20% to ₹994 Up from ₹831, the current price target is an average from 4 analysts. New target price is 16% above last closing price of ₹857. Stock is up 127% over the past year. The company is forecast to post earnings per share of ₹47.70 next year compared to a net loss per share of ₹13.72 last year. Reported Earnings • May 23
Full year 2024 earnings released: ₹13.72 loss per share (vs ₹24.56 loss in FY 2023) Full year 2024 results: ₹13.72 loss per share (improved from ₹24.56 loss in FY 2023). Revenue: ₹40.9b (up 11% from FY 2023). Net loss: ₹1.25b (loss narrowed 44% from FY 2023). Revenue is forecast to grow 9.9% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Breakeven Date Change • May 23
Forecast breakeven date pushed back to 2025 The 4 analysts covering Strides Pharma Science previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of ₹4.20b in 2025. Earnings growth of 84% is required to achieve expected profit on schedule. Ankündigung • May 16
Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024 Strides Pharma Science Limited announced that they will report Q4, 2024 results on May 22, 2024 Ankündigung • May 01
Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director Strides Pharma Science Limited approved appointment of Mr. Ameet P Hariani (DIN: 00087866) as Independent Director of the Company. Reported Earnings • Jan 31
Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023) Third quarter 2024 results: ₹0.49 loss per share (improved from ₹8.86 loss in 3Q 2023). Revenue: ₹10.4b (up 20% from 3Q 2023). Net loss: ₹44.8m (loss narrowed 94% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Price Target Changed • Jan 31
Price target increased by 10% to ₹730 Up from ₹662, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of ₹698. Stock is up 146% over the past year. The company is forecast to post earnings per share of ₹3.60 next year compared to a net loss per share of ₹24.56 last year. Ankündigung • Jan 23
Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024 Strides Pharma Science Limited announced that they will report Q3, 2024 results on Jan 30, 2024 Ankündigung • Nov 23
Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit Strides Pharma Science Limited (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Sodium Sulphate, Pot potassium Sulphate and Magnesium Sulphate Oral Solution 17.5g/3.13g/1.6g per 6 ounces (Product) from the United States Food & Drug Administration (USFDA). The Product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Suprep Bowel Prep Kit Oral Solution 17.5g /3.13g/1.6g per 6 ounces of Braintree Laboratories Inc. (Braintree). The approval bolsters the Company's portfolio of products in bowel preparation that spans both prescription and over the counter offerings. The Product has a market size of USD 143 million per IQVIA. The Product will be manufactured at the company's facility in Bengaluru. The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230+ ANDAs have been approved. The company has set a target to launch 60 new products over three years in the US. Buying Opportunity • Nov 03
Now 21% undervalued Over the last 90 days, the stock is up 5.6%. The fair value is estimated to be ₹596, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Meanwhile, the company became loss making. Ankündigung • Oct 31
Strides Pharma Science Limited Announces Change in Management Strides Pharma Science Limited announced that Resignation of Mr. Christoph Funke, Chief Operating Officer of the Company effective February 29, 2024. Appointment of Mr. Ramaraju PVS as the Chief Operating Officer of the Company effective March 1, 2024. Ram will join the rolls of Strides effective November 1, 2023 and will work with Christoph to transition his role during the next 4 months. Ram has served in multiple leadership capacities in Strides Pharma and later with Stelis Biopharma, primarily focusing on quality and manufacturing Operations. With thirty years of pharmaceutical industry experience, he has dedicated over sixteen years to the Strides Group, demonstrating a long-term commitment and amassing a wealth of industry knowledge. Throughout his illustrious career, he has also been associated with reputable organizations like Dr. Reddy's, USV andUnichem. Ram is a post-graduate in Pharmaceutical Chemistry from BITSPilani. Reported Earnings • Oct 31
Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023) Second quarter 2024 results: ₹14.54 loss per share (down from ₹0.47 profit in 2Q 2023). Revenue: ₹10.4b (up 15% from 2Q 2023). Net loss: ₹1.31b (down ₹1.36b from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Ankündigung • Oct 21
Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023 Strides Pharma Science Limited announced that they will report Q2, 2024 results on Oct 30, 2023 New Risk • Sep 26
New major risk - Revenue and earnings growth Earnings have declined by 53% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.3x net interest cover). Earnings have declined by 53% per year over the past 5 years. Ankündigung • Sep 16
Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets Strides Pharma Science Limited (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received tentative approval for Dolutegravir 50mg tablets from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Tivicay Tablets of ViiV Healthcare Company. The approval adds to a list of products that Strides has approved under the PEPFAR pathway taking the total to 13 products. The Dolutegravir 50 mg tablet has a market opportunity in the US of USD 1,345 million per IQVIA. The products will be manufactured at the company's facility in Bengaluru. The conversion of this tentative approval to a full approval is expected upon expiry of the constraining patents. The PEPFAR tentative approval for Strides qualifies the Company to participate in global donor funded programs that procure this lifesaving medicine and it is supplied in 126 countries. As of full year 2022, donor procurement for D Absolutegravir 50mg tablet is estimated at a value of USD 35 million. This product further strengthens the available offerings in HIV treatment from Strides. The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230+ ANDAs have been approved. The company has set a target to launch 60 new products over three years in the US. Ankündigung • Sep 02
Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy Strides Pharma Science Limited announced the resignation of Mr. Ankit Gupta as Vice President and Head of Corporate Development and Strategy of the Company for pursuing opportunities outside the Company. Resignation is effective closing business hours of August 31, 2023. Price Target Changed • Aug 04
Price target increased by 10% to ₹530 Up from ₹481, the current price target is an average from 2 analysts. New target price is 18% above last closing price of ₹448. Stock is up 30% over the past year. The company is forecast to post earnings per share of ₹23.55 next year compared to a net loss per share of ₹24.55 last year. Reported Earnings • Aug 04
First quarter 2024 earnings released: ₹0.79 loss per share (vs ₹15.13 loss in 1Q 2023) First quarter 2024 results: ₹0.79 loss per share (improved from ₹15.13 loss in 1Q 2023). Revenue: ₹9.30b (down 1.1% from 1Q 2023). Net loss: ₹71.1m (loss narrowed 95% from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jul 28
Upcoming dividend of ₹1.50 per share at 0.3% yield Eligible shareholders must have bought the stock before 04 August 2023. Payment date: 27 September 2023. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%). Ankündigung • Jul 26
Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023 Strides Pharma Science Limited announced that they will report Q1, 2024 results on Aug 02, 2023 Ankündigung • May 26
Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023 Strides Pharma Science Limited announced that at the board meeting held on May 25, 2023 recommended final dividend of INR. 1.50/- per equity share of INR. 10/- each (at the rate of 15%) for financial year ended March 31, 2023. Dividend will be paid within 30 days from the date of Shareholders' approval at the upcoming Annual General Meeting (AGM) of the Company. Reported Earnings • May 26
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: ₹24.56 loss per share (improved from ₹51.28 loss in FY 2022). Revenue: ₹37.8b (up 23% from FY 2022). Net loss: ₹2.21b (loss narrowed 52% from FY 2022). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 9.2% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Ankündigung • May 19
Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023 Strides Pharma Science Limited announced that they will report Q4, 2023 results on May 25, 2023 Price Target Changed • May 17
Price target decreased by 7.2% to ₹462 Down from ₹498, the current price target is an average from 2 analysts. New target price is 23% above last closing price of ₹375. Stock is up 21% over the past year. The company is forecast to post a net loss per share of ₹26.80 next year compared to a net loss per share of ₹51.28 last year. Reported Earnings • Jan 25
Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022) Third quarter 2023 results: ₹8.86 loss per share (improved from ₹13.55 loss in 3Q 2022). Revenue: ₹8.91b (up 12% from 3Q 2022). Net loss: ₹800.3m (loss narrowed 34% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Ankündigung • Jan 18
Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023 Strides Pharma Science Limited announced that they will report Q3, 2023 results on Jan 24, 2023 Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Kausalya Santhanam was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. Independent Director Homi Khusrokhan was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • Nov 15
Strides Pharma Science Limited Announces Resignation of Director Strides Pharma Science Limited inform that Mr. Deepak Calian Vaidya (DIN: 00337276), Non-Executive Director of the Company has communicated his decision to step down from Directorship of the Company with effect from closing business hours of November 14, 2022, due to pre-occupation. Mr. Vaidya was associated with Strides since January 1998 and has made significant contributions in laying a solid foundation for taking Strides to the next level of growth with compliance and integrity as key pillars. Strides has benefited immensely by his experience and guidance at many junctures. Ankündigung • Nov 09
Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022 Strides Pharma Science Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Ankündigung • Aug 19
Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022 Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022, at 12:30 Indian Standard Time. Agenda: To receive, consider, approve and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2022, together with the Reports of Board of Directors and Auditors thereon; to consider the Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2022, and the Report of Auditors thereon; to consider re-appointment of Mr. Badree Komandur, retiring director, as an Executive Director; to consider re-appointment of M/s. B S R & Co. LLP as Statutory Auditors of the Company; and to consider other matters. Reported Earnings • Jul 30
First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022) First quarter 2023 results: ₹15.13 loss per share (up from ₹22.88 loss in 1Q 2022). Revenue: ₹9.54b (up 39% from 1Q 2022). Net loss: ₹1.36b (loss narrowed 34% from 1Q 2022). Over the next year, revenue is forecast to grow 24%, compared to a 12% growth forecast for the industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance. Ankündigung • Jul 23
Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022 Strides Pharma Science Limited announced that they will report Q1, 2023 results on Jul 29, 2022 Ankündigung • Jun 17
Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate Stelis Biopharma Limited and Strides Pharma Science Limited announced that it had received the European Union Goods Manufacturing Practices (EU-GMP) compliance certificate from the National Institute of Pharmacy and Nutrition, Hungary for two of its manufacturing facilities. Stelis' facility (Unit 2, Bengaluru, India) is an integrated manufacturing setup that leverages microbial and mammalian platforms for developing and commercializing biologics and biosimilars in multiple fill-finish formats, including cartridges, devices, pre-filled syringes, liquid, and lyophilized vials. The facility has the most modern equipment setup, including the use of industry- leading technologies like single-use bags and isolator-based manufacturing, offering significant operational flexibility. Stelis's small-scale cGMP manufacturing facility (Unit 1, Bengaluru, India) is designed to support small- scale commercial and cGMP clinical trial material generation and initial technology transfer activities across multiple modalities. The facility is equipped with high-throughput instrumentation that offers different analytical developmental and characterization services for a wide range of biopharmaceutical products conforming to global regulatory standards throughout their lifecycle. As an emerging CDMO partner for the global biopharmaceutical industry, Stelis is committed to offering end-to-end solutions for developing and commercializing biologics, biosimilars, and vaccines. The company has recently entered into marquee international partnerships and gained comprehensive experience in manufacturing biologics for diabetes, osteoporosis, and other therapeutic categories using mammalian and microbial systems from the pre-clinical stage through commercialization. With over USD 300 million in investments, Stelis has built a robust CDMO platform that offers one of APAC's drug substance capacities with over 48,000L across various modalities and drug product capacities exceeding 400 million units per annum. Ankündigung • May 31
Strides Receives USFDA Approval for Ibuprofen Oral Suspension Strides Pharma Science Limited (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Ibuprofen Oral Suspension USP, 100 mg/5 mL from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil). According to IQVIA MAT March 2022 data, the US market for Ibuprofen Oral Suspension USP, 100 mg/5 mL is approximately ~US$ 66 Mn. The product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market. The company has 274 cumulative ANDA filings (including recently acquired portfolio from Endo at Chestnut Ridge) with USFDA of which 250 ANDAs have been approved and 24 are pending approval. The company currently has ~60 commercialized products in the US and has set a target to launch ~ 20 new products every year from the combined portfolio. Reported Earnings • May 26
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: ₹51.28 loss per share (down from ₹28.40 profit in FY 2021). Revenue: ₹32.0b (down 3.4% from FY 2021). Net loss: ₹4.60b (down 281% from profit in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 14%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. Ankündigung • May 17
Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022 Strides Pharma Science Limited announced that they will report Q4, 2022 results on May 24, 2022 Price Target Changed • Apr 27
Price target decreased to ₹463 Down from ₹640, the current price target is an average from 2 analysts. New target price is 40% above last closing price of ₹331. Stock is down 62% over the past year. The company is forecast to post a net loss per share of ₹45.10 compared to earnings per share of ₹28.40 last year. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Homi Khusrokhan was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. Independent Director Homi Khusrokhan was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Recent Insider Transactions • Mar 05
Founder & Non-Executive Chairman recently bought ₹50m worth of stock On the 25th of February, Arun Pillai bought around 155k shares on-market at roughly ₹322 per share. This was the largest purchase by an insider in the last 3 months. This was Arun's only on-market trade for the last 12 months. Reported Earnings • Feb 13
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: ₹13.55 loss per share (down from ₹4.22 profit in 3Q 2021). Revenue: ₹7.94b (down 4.5% from 3Q 2021). Net loss: ₹1.22b (down 422% from profit in 3Q 2021). Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Ankündigung • Feb 11
Strides Pharma Science Limited announced that it expects to receive INR 485 million in funding from Karuna Business Solutions LLP Strides Pharma Science Limited announced a private placement of up to 4,000,000 warrants at a price of INR 485 per share for gross proceeds of INR 1,940,000,000 on February 10, 2022.The company will receive 25% of the exercise price of the warrants which is INR 485,000,000 as upfront payment and the balance will be received at the time of exercise of warrants. The company will issue warrants on preferential basis to Karuna Business Solutions LLP. Pursuant to the transaction, the stake of the investor will increase from 1.36 to 5.57%. The transaction has been approved by board of directors and is subject to approval from extraordinary general meeting of shareholders to be held on March 12, 2022. Price Target Changed • Nov 12
Price target decreased to ₹735 Down from ₹843, the current price target is an average from 6 analysts. New target price is 45% above last closing price of ₹509. Stock is down 25% over the past year. The company is forecast to post a net loss per share of ₹32.60 compared to earnings per share of ₹28.40 last year. Reported Earnings • Nov 11
Second quarter 2022 earnings released: ₹18.12 loss per share (vs ₹7.38 profit in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹7.44b (down 6.3% from 2Q 2021). Net loss: ₹1.63b (down 346% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Recent Insider Transactions • Sep 23
Insider recently sold ₹1.5m worth of stock On the 20th of September, R. Aravinda sold around 3k shares on-market at roughly ₹602 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹14m. Insiders have been net sellers, collectively disposing of ₹167m more than they bought in the last 12 months. Price Target Changed • Sep 15
Price target decreased to ₹857 Down from ₹934, the current price target is an average from 6 analysts. New target price is 38% above last closing price of ₹622. Stock is down 11% over the past year. Recent Insider Transactions • Aug 14
Insider recently sold ₹14m worth of stock On the 10th of August, Bharat Shah sold around 20k shares on-market at roughly ₹701 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹146m. Insiders have been net sellers, collectively disposing of ₹574m more than they bought in the last 12 months. Reported Earnings • Aug 09
First quarter 2022 earnings released: ₹22.88 loss per share (vs ₹11.56 profit in 1Q 2021) The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: ₹6.88b (down 12% from 1Q 2021). Net loss: ₹2.05b (down 298% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Aug 07
Less than half of directors are independent Following Non-Executive Chairman Aditya Puri's arrival on 01 August 2021, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Vineeta Rai was the last independent director to join the board, commencing their role in the last week. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Jul 29
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 05 August 2021. Payment date: 03 October 2021. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.8%). 
